Overview New real‑world data from the 2024-2025 RSV season indicate that nirsevimab, a monoclonal antibody given to infants to prevent severe respiratory syncytial virus (RSV) infection, provides powerful protection. In a recent research letter analyzing administration patterns and hospitalizations, researchers report a clear reduction in RSV-related hospital stays among U.S. infants who received nirsevimab compared…